Xavier Quantin
Inserm · 262 works · 11,324 citations · h-index 32
Top works
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- 1396P HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
- Effects of cigarette smoking on reproduction
- Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients
- Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study
- Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
- Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin
- Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data
- Cytokeratins as Serum Markers in Lung Cancer: A Comparison of CYFRA 21-1 and TPS
- 1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
- Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
- Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO* analysis of prognostic factors
- Concomitant brain radiotherapy and vinorelbine–ifosfamide–cisplatin chemotherapy in brain metastases of non-small cell lung cancer
- Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
- Predictive Factors of Tumor Response and Prognostic Factors of Survival during Lung Cancer Chemotherapy
- Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort
- Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers
- Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
- Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort